VEGFR2/CD309 anticorps

N° du produit ABIN967481

Détail du produit anti-VEGFR2/CD309 anticorps

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS)

Marque: BD Pharmingen™

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Sodium azide is a reversible inhibitor of oxidative metabolism, therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Mouse Flk1 and human IgG1 fusion protein

Clone: Avas 12alpha1

Isotype: IgG2a kappa

Information d'application

Indications d'application: For immunohistochemistry application, we recommend to use purified Avas 12alpha1 mAb in our special formulation for immunohistochemistry.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4° C.

Références pour anticorps anti-VEGFR2/CD309 (ABIN967481)

Kataoka, Takakura, Nishikawa, Tsuchida, Kodama, Kunisada, Risau, Kita, Nishikawa: "Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells." dans: Development, growth & differentiation, Vol. 39, Issue 6, pp. 729-40, (1998) (PubMed).

Nishikawa, Nishikawa, Hirashima, Matsuyoshi, Kodama: "Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages." dans: Development (Cambridge, England), Vol. 125, Issue 9, pp. 1747-57, (1998) (PubMed).

Nishikawa, Nishikawa, Kawamoto, Yoshida, Kizumoto, Kataoka, Katsura: "In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos." dans: Immunity, Vol. 8, Issue 6, pp. 761-9, (1998) (PubMed).

Hanahan: "Signaling vascular morphogenesis and maintenance." dans: Science (New York, N.Y.), Vol. 277, Issue 5322, pp. 48-50, (1997) (PubMed).

Shalaby, Ho, Stanford, Fischer, Schuh, Schwartz, Bernstein, Rossant: "A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis." dans: Cell, Vol. 89, Issue 6, pp. 981-90, (1997) (PubMed).

Shalaby, Rossant, Yamaguchi, Gertsenstein, Wu, Breitman, Schuh: "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice." dans: Nature, Vol. 376, Issue 6535, pp. 62-6, (1995) (PubMed).

Millauer, Wizigmann-Voos, Schnürch, Martinez, Møller, Risau, Ullrich: "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis." dans: Cell, Vol. 72, Issue 6, pp. 835-46, (1993) (PubMed).

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: Flk1 (VEGFR2 Produits)

Synonymes: anticorps CD309, anticorps FLK1, anticorps VEGFR, anticorps VEGFR2, anticorps 6130401C07, anticorps Flk-1, anticorps Flk1, anticorps Krd-1, anticorps Ly73, anticorps VEGFR-2, anticorps sVEGFR-2, anticorps Vegfr-2, anticorps FLK-1, anticorps flk-1, anticorps vegfr-2, anticorps KDR, anticorps FLK/KDR, anticorps flk1, anticorps flk1b, anticorps kdrb, anticorps si:busm1-205d10.1, anticorps si:ch211-254j6.1, anticorps si:ch211-278f21.4, anticorps wu:fc31a09, anticorps fk52c05, anticorps flk, anticorps kdr, anticorps kdra, anticorps vegfr2, anticorps vegfr4, anticorps vegr2, anticorps wu:fk52c05, anticorps kinase insert domain receptor, anticorps kinase insert domain protein receptor, anticorps vascular endothelial growth factor receptor kdr-like, anticorps kinase insert domain receptor (a type III receptor tyrosine kinase), anticorps kinase insert domain receptor like, anticorps KDR, anticorps Kdr, anticorps LOC100136647, anticorps kdr, anticorps kdrl

Sujet: The Avas 12alpha1 antibody reacts with fetal liver kinase 1 (Flk-1), a receptor protein tyrosine kinase closely related to CD117 (c-kit) and CD140a (PDGF Receptor alpha chain) of the immunoglobulin superfamily. Flk-1, also known as VEGF Receptor-2 (VEGF-R2), is a receptor for vascular endothelial growth factor (VEGF). It is expressed, at the mRNA and protein levels, on distinct sets of mesoderm during gastrulation and on endothelial cells in embryonic tissues. In vivo and in vitro studies indicate that Flk-1 is required for the embryonic development of vascular endothelial and hematopoietic cells.
Synonyms: VEGF-R2, Ly-73

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling